2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary …
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary
syndromes (ACS) are substantial contributors to morbidity and mortality across Europe …
syndromes (ACS) are substantial contributors to morbidity and mortality across Europe …
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?
Abstract Purpose of Review Atherosclerotic cardiovascular disease (ASCVD) is a leading
cause of premature death. Lipid disorders, particularly elevated serum low-density …
cause of premature death. Lipid disorders, particularly elevated serum low-density …
[HTML][HTML] 2023: The year in cardiovascular disease–the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
In 2023 there are still even 75% of patients over the target of low-density lipoprotein
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …
Application of proteomics for novel drug discovery and risk prediction optimisation in stroke and myocardial infarction: a review of in-human studies
The use of proteomics in human studies investigating stroke and myocardial infarction (MI)
has been increasing, prompting a review of the literature. This revealed proteinaceous …
has been increasing, prompting a review of the literature. This revealed proteinaceous …
Zilebesiran—the first siRNA-based drug in hypertensiology: why is it needed, and will it change the treatment approach of hypertension?
S Surma, S Oparil - Arterial Hypertension, 2024 - journals.viamedica.pl
Arterial hypertension is the most common cardiovascular risk factor in the world. The
prevalence of hypertension has doubled over the last 30 years. Despite the availability of …
prevalence of hypertension has doubled over the last 30 years. Despite the availability of …
Nutrition, nutraceuticals and bioactive compounds in the prevention and fight against inflammation
SARS-CoV-2—severe acute respiratory syndrome coronavirus 2; MetS—metabolic
syndrome; DMT2—diabetes mellitus type 2; MAFLD—metabolic-associated fatty liver …
syndrome; DMT2—diabetes mellitus type 2; MAFLD—metabolic-associated fatty liver …
Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association
Position paper of the Polish expert group on the use of pitavastatin in the treatment of lipid
disorders in Poland endorsed by the Polish Lipid Association Journals Advances in Dermatology …
disorders in Poland endorsed by the Polish Lipid Association Journals Advances in Dermatology …
[HTML][HTML] Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk …
Introduction Classical risk factors such as hypertension, hypercholesterolemia, pre-diabetes,
diabetes and obesity can predict adverse cardiovascular events, but they are less prognostic …
diabetes and obesity can predict adverse cardiovascular events, but they are less prognostic …
Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia
Q Fang, X Lu, Y Zhu, X Lv, F Yu, X Ma, B Liu… - Cell Reports …, 2024 - cell.com
Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein
receptor (LDLR) and mediates its internalization and degradation, resulting in an increase in …
receptor (LDLR) and mediates its internalization and degradation, resulting in an increase in …
Celebrating the 90th birthday of the scientist who discovered statins: Akira Endō
In 1971, Dr Akira Endō (Figure 1A), working at the Sankyo company in Tokyo, speculated
that fungi not only contained antibiotics but also inhibitors of other processes, such as …
that fungi not only contained antibiotics but also inhibitors of other processes, such as …